PacBio (NASDAQ: PACB) announced on August 5, 2026 that SPRQ-Nx chemistry will raise per-run HiFi output on its Vega benchtop sequencer from 60 Gb to 90 Gb, per the company's press release. The U.S. list price per run drops from $1,100 to $995. A software update adds two-hour and four-hour run modes plus regulated-laboratory compliance controls.
What changes for a Vega lab, in numbers?
Three figures carry the announcement. Output rises 50 percent, from 60 Gb to 90 Gb of HiFi data per run, because SPRQ-Nx brings the same core chemistry used on the high-throughput Revio system down to the benchtop instrument, per the company. Cost per gigabase falls approximately 40 percent, the combined effect of higher yield and the lower per-run price. DNA input requirements drop from 2 micrograms to as low as 500 nanograms, which matters for samples where material is the binding constraint.
The software half of the update is aimed at the regulated-laboratory market. It introduces two-hour and four-hour sequencing runs, aligns Vega's multiomic analysis with Revio through new 5-hydroxymethylcytosine and improved methylation callers, and adds user login and audit-tracking capabilities designed to support customers' 21 CFR Part 11 compliance efforts, per the announcement.
Why does the 21 CFR Part 11 angle matter?
Because regulated use is the growth frontier for sequencing instruments. Part 11 is the FDA regulation governing electronic records and signatures, and instruments that support it with authentication and audit logging can be adopted into clinical-trial and diagnostic-development workflows more readily than instruments that cannot. A benchtop long-read system with compliance controls is positioned for laboratories that need in-house HiFi capability under documented workflows rather than sending samples out.
Sequencing in regulated settings is not new, but long-read HiFi on a benchtop footprint with these controls is the specific combination PacBio is claiming. Availability timing, per the release: the chemistry is expected to be available to ship, and the software update available to download, by the end of August 2026.
What is the competitive read?
The move compresses the gap between PacBio's own high-throughput and benchtop lines, and it prices benchtop HiFi more aggressively at 995 dollars per run in consumables. Short-read benchtop instruments remain cheaper per genome at scale; the HiFi claim is read length plus methylation direct detection in the same run, which short reads do not provide. For labs doing rare-variant, structural-variant, or methylation-sensitive work, the effective comparison is against outsourcing or against a larger installed system, not against a small benchtop short-read box.
What is not yet disclosed: installed-base figures for Vega, take-up expectations for SPRQ-Nx, and any pricing for markets outside the United States. The output, pricing, and software claims in this piece are company-claimed, per PacBio's announcement and coverage of it.
This article is technology news coverage, not medical or purchasing advice. It does not evaluate any product for any laboratory's specific use. Qualified professionals should assess suitability for intended applications.
